Total Payments
$69,125
2022 Payments
$30.00
Companies
4
Transactions
14
Payment Breakdown by Category
Research$68,898 (99.7%)
Travel$173.24 (0.3%)
Education$30.00 (0.0%)
Food & Beverage$24.13 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $68,898 | 11 | 99.7% |
| Travel and Lodging | $173.24 | 1 | 0.3% |
| Education | $30.00 | 1 | 0.0% |
| Food and Beverage | $24.13 | 1 | 0.0% |
Payments by Type
Research
$68,898
11 transactions
General
$227.37
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Avid Radiopharmaceuticals, Inc. | $34,674 | 2 | $0 (2017) |
| Genentech, Inc. | $24,009 | 4 | $0 (2017) |
| Eli Lilly and Company | $10,412 | 7 | $0 (2018) |
| Eisai Inc. | $30.00 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $30.00 | 1 | Eisai Inc. ($30.00) |
| 2018 | $5,962 | 3 | Eli Lilly and Company ($5,962) |
| 2017 | $63,134 | 10 | Avid Radiopharmaceuticals, Inc. ($34,674) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2022 | Eisai Inc. | — | Education | Cash or cash equivalent | $30.00 | General |
| 02/13/2018 | Eli Lilly and Company | — | — | Cash or cash equivalent | $4,791.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DELAYED-START STUDY OF LY3314814 AZD3293 IN EARLY ALZHEIMER'S DISEASE DEMENTIA EXTENSION OF STUDY AZES, THE AMARANTH STUDY | ||||||
| 01/26/2018 | Eli Lilly and Company | — | — | In-kind items and services | $795.75 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DELAYED-START STUDY OF LY3314814 AZD3293 IN EARLY ALZHEIMER'S DISEASE DEMENTIA EXTENSION OF STUDY AZES, THE AMARANTH STUDY | ||||||
| 01/15/2018 | Eli Lilly and Company | — | — | In-kind items and services | $375.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE THE EVOLVE-1 STUDY | ||||||
| 06/09/2017 | Avid Radiopharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $24.13 | General |
| 05/30/2017 | Avid Radiopharmaceuticals, Inc. | AMYVID (Drug) | — | Cash or cash equivalent | $34,650.00 | Research |
| Study: REGISTRY OF AMYLOID POSITIVE PATIENTS FOR ALZHEIMER'S DISEASE DRUG RESEARCH TRIALS • Category: Neuroscience | ||||||
| 05/02/2017 | Genentech, Inc. | Non-Covered Product (Drug) | — | Cash or cash equivalent | $3,035.00 | Research |
| Study: PRODROMAL TO MILD AD • Category: None | ||||||
| 03/27/2017 | Genentech, Inc. | Non-Covered Product (Drug) | — | Cash or cash equivalent | $4,594.25 | Research |
| Study: PRODROMAL TO MILD AD • Category: None | ||||||
| 03/16/2017 | Eli Lilly and Company | — | — | In-kind items and services | $779.81 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DELAYED-START STUDY OF LY3314814 AZD3293 IN EARLY ALZHEIMER'S DISEASE DEMENTIA EXTENSION OF STUDY AZES, THE AMARANTH STUDY | ||||||
| 03/08/2017 | Genentech, Inc. | Non-Covered Product (Drug) | — | Cash or cash equivalent | $10,125.00 | Research |
| Study: PRODROMAL TO MILD AD • Category: None | ||||||
| 02/01/2017 | Genentech, Inc. | Non-Covered Product (Drug) | — | Cash or cash equivalent | $6,255.00 | Research |
| Study: PRODROMAL TO MILD AD • Category: None | ||||||
| 01/27/2017 | Eli Lilly and Company | — | — | In-kind items and services | $2,535.00 | Research |
| Study: A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY | ||||||
| 01/25/2017 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $173.24 | General |
| 01/13/2017 | Eli Lilly and Company | — | — | In-kind items and services | $962.27 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-1 STUDY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| REGISTRY OF AMYLOID POSITIVE PATIENTS FOR ALZHEIMER'S DISEASE DRUG RESEARCH TRIALS | Avid Radiopharmaceuticals, Inc. | $34,650 | 1 |
| PRODROMAL TO MILD AD | Genentech, Inc. | $24,009 | 4 |
| A RANDOMIZED, DOUBLE-BLIND, DELAYED-START STUDY OF LY3314814 AZD3293 IN EARLY ALZHEIMER'S DISEASE DEMENTIA EXTENSION OF STUDY AZES, THE AMARANTH STUDY | Eli Lilly and Company | $6,367 | 3 |
| A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY | Eli Lilly and Company | $2,535 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-1 STUDY | Eli Lilly and Company | $962.27 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE THE EVOLVE-1 STUDY | Eli Lilly and Company | $375.00 | 1 |
About Dr. Jack Klapper, MD
Dr. Jack Klapper, MD is a Specialist healthcare provider based in Denver, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/16/2013. The National Provider Identifier (NPI) number assigned to this provider is 1871936278.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jack Klapper, MD has received a total of $69,125 in payments from pharmaceutical and medical device companies, with $30.00 received in 2022. These payments were reported across 14 transactions from 4 companies. The most common payment nature is "" ($68,898).
Ad
Practice Information
- Specialty Specialist
- Other Specialties Research Study
- Location Denver, CO
- Active Since 04/16/2013
- Last Updated 04/16/2013
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1871936278
Products in Payments
- AMYVID (Drug) $34,650
- Non-Covered Product (Drug) $24,009
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Denver
Dr. Raymond Kim, Md, MD
Specialist — Payments: $3.7M
Specialist $3.7M
Dr. Anthony Canfield, M.d, M.D
Specialist — Payments: $953,125
Specialist $953,125
Dr. James Chappell, Md, MD
Specialist — Payments: $538,342
Specialist $538,342
Dr. Barbara Schwartzberg, M.d, M.D
Specialist — Payments: $447,617
Specialist $447,617
Dr. Giancarlo Barolat-Romana, Md, MD
Specialist — Payments: $328,167
Specialist $328,167
Michael Schiff, M.d, M.D
Specialist — Payments: $244,233
Specialist $244,233